Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Corcept Therapeutics Incorporated - Common Stock (NQ:CORT)

39.06 -1.41 (-3.48%)
Streaming Delayed Price Updated: 10:19 AM EDT, Mar 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Corcept Therapeutics Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
News headline image
MarketMinute: Corcept Therapeutics (CORT) Surges 19.66% on Surprise FDA Approval and Oncology Breakthrough
The biotechnology sector witnessed a seismic shift on March 26, 2026, as shares of Corcept Therapeutics (NASDAQ: CORT) surged 19.66% in heavy trading. The rally, which added nearly $1 billion to the... 
Via MarketMinute
Topics Intellectual Property
News headline image
The Second Act: A Deep-Dive into Corcept Therapeutics and the FDA Approval of Lifyorli
March 26, 2026 Introduction Yesterday, March 25, 2026, Corcept Therapeutics (NASDAQ: CORT) reached a defining milestone that has fundamentally altered its investment profile: the early FDA approval of... 
Via Finterra
Topics Economy Intellectual Property
News headline image
Corcept Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Corcept Therapeutics Incorporated - CORT
From SkyMedia, LLC
Via GlobeNewswire
Corcept Therapeutics Inc (NASDAQ:CORT): A GARP Pick with Accelerating Growth and a Solid Financial Base ↗
Via Chartmill
News headline image
Why Investors Strapped a Rocket to Corcept Therapeutics Stock on Wednesday ↗
A top regulator approved one of its drugs that afternoon. 
Via The Motley Fool
Wednesday's session: top gainers and losers ↗
Via Chartmill
News headline image
FDA Approves Corcept’s Selective Glucocorticoid Receptor Antagonist Lifyorli™ (relacorilant) Plus Nab-Paclitaxel for Treatment of Patients with Platinum-Resistant Ovarian Cancer
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
What's Behind The Jump In Corcept Therapeutics Stock? ↗
Shares of Corcept Therapeutics Incorporated (NASDAQ: CORT) are soaring Wednesday after the FDA approved a treatment for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary... 
Via Benzinga
News headline image
Deadline Approaching for Investors of Corcept Therapeutics, Inc. (CORT) - Contact Kaplan Fox Before April 21, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
Deadline Approaching for Investors of Corcept Therapeutics, Inc. (CORT) - Contact Kaplan Fox Before April 21, 2026
NEW YORK, NY - March 25, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Corcept Therapeutics, Inc. (“Corcept” or the “Company”) (NASDAQ:... 
Via TheNewswire.com
Topics Lawsuit
News headline image
Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
From Kahn Swick & Foti, LLC
Via GlobeNewswire
News headline image
Kaplan Fox Continues to Alert Investors of a Securities Class Action Against Corcept Therapeutics, Inc. (NASDAQ: CORT) - Deadline on April 21, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
Kaplan Fox Continues to Alert Investors of a Securities Class Action Against Corcept Therapeutics, Inc. (NASDAQ: CORT) - Deadline on April 21, 2026
NEW YORK, NY - March 24, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Corcept Therapeutics, Inc. (“Corcept” or the “Company”) (NASDAQ:... 
Via TheNewswire.com
Topics Lawsuit
News headline image
CORT DEADLINE NOTICE: Corcept Therapeutics Incorporated Investors Encouraged to Contact Kirby McInerney LLP By April 21, 2026
From Kirby McInerney LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Corcept Therapeutics Incorporated of Class Action Lawsuit and Upcoming Deadlines – CORT
From Pomerantz LLP
Via GlobeNewswire
News headline image
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Corcept Therapeutics Incorporated to Secure Counsel Before Important Deadline in Securities Class Action – CORT
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
Q4 Earnings Outperformers: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Stocks
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, incl... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
CORT INVESTOR ALERT: Contact Kirby McInerney LLP About Securities Class Action Lawsuit On Behalf of Corcept Therapeutics Incorporated Investors
From Kirby McInerney LLP
Via GlobeNewswire
News headline image
Corcept Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Corcept Therapeutics Incorporated - CORT
From SkyMedia, LLC
Via GlobeNewswire
News headline image
Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
From Kahn Swick & Foti, LLC
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Corcept Therapeutics Incorporated of Class Action Lawsuit and Upcoming Deadlines – CORT
From Pomerantz LLP
Via GlobeNewswire
News headline image
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Corcept Therapeutics Incorporated (CORT)
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
CORCEPT THERAPEUTICS INCORPORATED (CORT) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Corcept Therapeutics Incorporated Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
Corcept Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Corcept Therapeutics Incorporated - CORT
From SkyMedia, LLC
Via GlobeNewswire
News headline image
1 High-Flying Stock with Impressive Fundamentals and 2 We Avoid
Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match. The flip side though is that these lo... 
Via StockStory
Topics Credit Cards
News headline image
Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
From Kahn Swick & Foti, LLC
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Urges Navan and Corcept Investors with Large Losses to Contact the Firm Before the Upcoming Lead Plaintiff Deadlines
From Bragar Eagel & Squire
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.